PanCAN Provides No-Cost Pancreatic Enzyme Therapy to Clinical Trial Participants

The Pancreatic Cancer Action Network (PanCAN) is providing pancrelipase, a pancreatic enzyme drug, for supportive care use to participants enrolled in the Precision Promise adaptive clinical trial. This treatment is used for patients experiencing pancreatic exocrine insufficiency (PEI), which often develops among patients with pancreatic cancer. These patients do not have enough pancreatic enzymes, which break down and absorb food, and often experience poor quality of life and worse outcomes. Read More

Efficacy of Seribantumab in Patients With Advanced Solid Tumors and an NRG1 Gene Fusion

The Clinical study of REsponse to Seribantumab in TumOrs with NEuregulin 1 (NRG1) fusions, or CRESTONE, is a single arm phase 2 study exploring the anti-tumor activity and tolerability of seribantumab in patients with advanced solid tumors and an NRG1 gene fusion. Read More

Top Advances in CLL Treatment Over the Past Decade

Over the past decade, the FDA has approved multiple new targeted therapies for chronic lymphocytic leukemia (CLL) that are encouraging a move toward chemotherapy-free treatment. Medical professionals have seen that patients are living longer under these treatments, often with a higher quality of life. Read More

Pembrolizumab Meets Dual Endpoints in KEYNOTE-522 Trial for Triple-Negative Breast Cancer

Pembrolizumab met its dual endpoints of event-free survival (EFS) and pathological complete response (pCR) at the interim analysis of the phase 3 KEYNOTE-522 trial, which explored the anti–PD-1 therapy’s efficacy in high-risk, early-stage, triple-negative breast cancer (TNBC). Read More

Late-Breaking Developments From the POSEIDON Trial

Results of late-breaking developments from the POSEIDON Phase III trial revealed improved overall survival (OS) with a limited course of five cycles of tremelimumab added to durvalumab plus platinum chemotherapy. Read More.